CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced positive preclinical results which demonstrated naltrexone for extended-release injectable suspension (XR-NTX) was more effective in an animal model of substance abuse compared to oral naltrexone therapy. The data were presented in an oral session at the 35th Annual Meeting and Exposition of the Controlled Release Society in New York City.
